Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AKBA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in… NCT06901505 · Anemia of Chronic Kidney Disease Erythropoiesis-Stimulating Agent (ESA), Vadadustat | AKBA Akebia Therapeutics | Phase 3 | Completed | 353 | Aug 12, 2026 | Registry ↗ |
| Nov 9, 2026 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) NCT07268638 · Focal Segmental Glomerulosclerosis Praliciguat (Part A), Placebo (Part A) | AKBA Akebia Therapeutics | Phase 2 | Recruiting | 60 | Jun 2027 | Registry ↗ |
| Oct 6, 2026 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants NCT07429006 · Healthy Volunteers AKB-9090, Placebo | AKBA Akebia Therapeutics | Phase 1 | Recruiting | 44 | Dec 2026 | Registry ↗ |
| Oct 1, 2026 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants Wi… NCT06419205 · IgA Nephropathy, Lupus Nephritis (LN) ADX-097 | AKBA Akebia Therapeutics | Phase 2 | Recruiting | 30 | Feb 2028 | Registry ↗ |
| Oct 1, 2025 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia… NCT05082584 · Anemia of Chronic Kidney Disease Vadadustat | AKBA Akebia Therapeutics | Phase 3 | Withdrawn | 0 | Jul 2026 | Registry ↗ |
| Oct 1, 2025 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia… NCT05082571 · Anemia of Chronic Kidney Disease vadadustat | AKBA Akebia Therapeutics | Phase 3 | Withdrawn | 0 | Jul 2026 | Registry ↗ |
| May 22, 2025 | Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly… NCT04313153 · Anemia Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Completed | 319 | Nov 26, 2021 | Registry ↗ |
| Jan 15, 2025 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimu… NCT04707768 · Anemia Associated With Chronic Kidney Disease (CKD) Vadadustat, Mircera® | AKBA Akebia Therapeutics | Phase 3 | Completed | 456 | Jan 6, 2023 | Registry ↗ |
| Sep 29, 2022 | Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa NCT03799627 · Anemia, Dialysis-dependent Chronic Kidney Disease Vadadustat, Epoetin Alfa | AKBA Akebia Therapeutics | Phase 2 | Completed | 175 | Jun 5, 2020 | Registry ↗ |
| Sep 15, 2022 | A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Prese… NCT03254485 · Heart Failure With Preserved Ejection Fraction IW-1973, Placebo Oral Tablet | AKBA Akebia Therapeutics | Phase 2 | Completed | 196 | Aug 19, 2019 | Registry ↗ |
| Sep 15, 2022 | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy… NCT03217591 · Type 2 Diabetes Mellitus With Diabetic Nephropathy IW-1973, IW-1973 | AKBA Akebia Therapeutics | Phase 2 | Completed | 156 | Aug 20, 2019 | Registry ↗ |
| Jul 21, 2022 | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia NCT01906489 · Anemia, Chronic Kidney Disease AKB-6548, Placebo | AKBA Akebia Therapeutics | Phase 2 | Completed | 210 | Sep 3, 2014 | Registry ↗ |
| Jul 18, 2022 | Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Ane… NCT02865850 · Anemia, Dialysis-Dependent Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Completed | 369 | Jan 31, 2020 | Registry ↗ |
| Jul 1, 2022 | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease… NCT02260193 · Anemia, End Stage Renal Disease AKB-6548, AKB-6548 | AKBA Akebia Therapeutics | Phase 2 | Completed | 94 | Jul 22, 2015 | Registry ↗ |
| Jul 1, 2022 | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia NCT01381094 · Anemia, Kidney Disease AKB-6548, Placebo | AKBA Akebia Therapeutics | Phase 2 | Completed | 93 | Feb 16, 2012 | Registry ↗ |
| Jul 1, 2022 | Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia NCT01235936 · Anemia, Kidney Disease AKB-6548 | AKBA Akebia Therapeutics | Phase 2 | Completed | 10 | Apr 13, 2011 | Registry ↗ |
| Jun 28, 2022 | Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Dis… NCT04707573 · Chronic Kidney Disease Vadadustat | AKBA Akebia Therapeutics | Phase 2 | Completed | 22 | Sep 24, 2010 | Registry ↗ |
| Jun 28, 2022 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Partici… NCT02892149 · Anemia, Dialysis-Dependent Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Completed | 3,554 | Jan 16, 2020 | Registry ↗ |
| Jun 27, 2022 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Partici… NCT02680574 · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Completed | 1,725 | Jun 18, 2020 | Registry ↗ |
| Jun 27, 2022 | Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-depende… NCT02648347 · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Completed | 1,751 | Jun 4, 2020 | Registry ↗ |
| Apr 8, 2021 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent C… NCT03054350 · Anemia, Dialysis Dependent Chronic Kidney Disease Vadadustat, Placebo | AKBA Akebia Therapeutics | Phase 2 | Completed | 60 | Oct 24, 2017 | Registry ↗ |
| Apr 8, 2021 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Depende… NCT03054337 · Anemia, Non-dialysis Dependent Chronic Kidney Disease Vadadustat, Placebo | AKBA Akebia Therapeutics | Phase 2 | Completed | 51 | Jul 4, 2017 | Registry ↗ |
| Feb 21, 2021 | Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease… NCT03140722 · Anemia, Dialysis-Dependent Chronic Kidney Disease vadadustat, epoetin alfa | AKBA Akebia Therapeutics | Phase 2 | Terminated | 2 | Mar 21, 2018 | Registry ↗ |
| Oct 8, 2020 | Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics o… NCT04299633 · Healthy Volunteers Vadadustat, Sevelamer carbonate | AKBA Akebia Therapeutics | Phase 1 | Completed | 54 | Aug 2, 2020 | Registry ↗ |
| Sep 16, 2020 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis… NCT03992066 · Anemia Associated With Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 1 | Completed | 46 | May 5, 2020 | Registry ↗ |
| Mar 22, 2019 | Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide NCT03801759 · Drug Interaction Potentiation Vadadustat, Furosemide | AKBA Akebia Therapeutics | Phase 1 | Completed | 62 | Sep 30, 2018 | Registry ↗ |
| Mar 22, 2019 | Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin NCT03801746 · Drug Interaction Potentiation vadadustat, Rifampin | AKBA Akebia Therapeutics | Phase 1 | Completed | 40 | Aug 15, 2018 | Registry ↗ |
| Mar 22, 2019 | Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastat… NCT03801733 · Drug Interaction Potentiation Vadadustat, Simvastatin | AKBA Akebia Therapeutics | Phase 1 | Completed | 134 | Nov 24, 2018 | Registry ↗ |
| Mar 22, 2019 | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function NCT03799848 · Hepatic Impairment Vadadustat | AKBA Akebia Therapeutics | Phase 1 | Completed | 24 | Oct 18, 2018 | Registry ↗ |
| Mar 22, 2019 | Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat NCT03789032 · Drug Interaction Potentiation, Pharmacokinetics Vadadustat, Rabeprazole | AKBA Akebia Therapeutics | Phase 1 | Completed | 20 | Nov 9, 2018 | Registry ↗ |
| Mar 22, 2019 | A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and… NCT03657290 · Healthy vadadustat | AKBA Akebia Therapeutics | Phase 1 | Completed | 54 | Oct 16, 2018 | Registry ↗ |
| Mar 22, 2019 | A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets… NCT03639155 · Healthy vadadustat reference tablets, vadadustat test tablets | AKBA Akebia Therapeutics | Phase 1 | Completed | 50 | May 23, 2018 | Registry ↗ |
| Nov 14, 2018 | Effect of AKB-6548 on the Pharmacokinetics of Celecoxib NCT02502500 · Healthy Volunteers Celecoxib, AKB-6548 | AKBA Akebia Therapeutics | Phase 1 | Completed | 12 | Jul 2015 | Registry ↗ |
| Nov 14, 2018 | Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Hea… NCT02412449 · Healthy AKB-6548 tablet, reference formulation given in the fasted… | AKBA Akebia Therapeutics | Phase 1 | Completed | 18 | Apr 2015 | Registry ↗ |
| Nov 14, 2018 | Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548 NCT02327546 · Healthy Volunteers AKB-6548, Ferrous Sulfate | AKBA Akebia Therapeutics | Phase 1 | Completed | 10 | Dec 2014 | Registry ↗ |
| Nov 14, 2018 | Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers NCT02062203 · Healthy Volunteers AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dos… | AKBA Akebia Therapeutics | Phase 1 | Completed | 50 | Apr 2014 | Registry ↗ |
| Nov 5, 2018 | Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With… NCT03242967 · Anemia, Dialysis-Dependent Chronic Kidney Disease Vadadustat, Darbepoetin alfa | AKBA Akebia Therapeutics | Phase 3 | Withdrawn | 0 | Feb 12, 2018 | Registry ↗ |
37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances